Your browser doesn't support javascript.
loading
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+B-cell repopulation.
Sahi, Nitin Kumar; Abidi, Syed Muhammad Ali; Salim, Omar; Abraham, Roby; Kalra, Seema; Al-Araji, Adnan.
Afiliação
  • Sahi NK; Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom. Electronic address: n.sahi@nhs.net.
  • Abidi SMA; Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.
  • Salim O; Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.
  • Abraham R; Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.
  • Kalra S; Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.
  • Al-Araji A; Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.
Mult Scler Relat Disord ; 56: 103287, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34627005
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article